From October 18 to 20, VEMINSYN, together with its subsidiary Suzhou Shiguang Pharmaceutical Biotechnology Co., Ltd., was invited to attend AMWC China 2024 World Congress on Aesthetic Medicine and Anti-Aging held in Chengdu.
Making its debut at this premier aesthetic medicine event, Suzhou Shiguang Pharmaceutical presented innovative collagen products and a brand-new OEM brand for medical devices, providing new solutions for the aesthetic medicine industry.
Innovatively Developed Collagen Products | Precise Transmembrane Structure as a Unique Competitive Advantage
As an emerging material in the aesthetic medicine field in recent years, Type XVII Collagen has won growing preference among consumers for its excellent biocompatibility and remarkable anti-aging effects.
As the pioneer of customized collagen in China, Suzhou Shiguang Pharmaceutical is the first manufacturer of Type XVII Collagen featuring a precise transmembrane structure.Its Type XVII Collagen preserves the complete active domain with higher stability, which can boost the density and thickness of the dermis and stimulate the synthesis of endogenous Type XVII Collagen. It also remains in the human body for a longer duration after aesthetic medical procedures.
Representatives from Suzhou Shiguang Pharmaceutical showcased the invention patents of the product through on-site demonstrations and professional briefings, and elaborated in detail on the remarkable efficacy advantages of structurally intact Type XVII Collagen. The presentation earned extensive attention and high recognition from the experts and attendees at the event.
Brand-New Medical Device Brand | Three Proprietary Technologies Steal the Show
During the three-day conference, Suzhou Shiguang Pharmaceutical not only exhibited a wide range of its OEM products, but also presented 「Guangyuan Xinsheng」 — its brand-new upcoming OEM product line.As an emerging domestic medical device brand, Guangyuan Xinsheng garnered strong attention from industry peers and attendees right after its debut.
Guangyuan Xinsheng launched its inaugural series of recombinant collagen compound liquid dressings, integrating three proprietary technologies exclusively developed by Suzhou Shiguang Pharmaceutical:72-hour delayed freezing technology, ultra-low temperature micromolecular polymerization technology, and gradient water molecule sublimation technology.
These technologies effectively lock in collagen activity, rebuild collagen vitality from within, and revitalize the skin for a renewed, glowing condition.
Enriched with ample doses of our exclusive high-activity recombinant Type XVII Collagen, the brand launches three lines—XinYuan Bottle, XinAi Bottle, XinYang Bottle—tailored for facial, intimate, and hair/scalp applications respectively.These products stand out for their genuine transmembrane structure, high biocompatibility, high bioactivity, and high purity.
XinYuan Bottle | Facial Skin
Product Advantages:Delivers unique basement membrane zone repair effects, comprehensively improving skin concerns including roughness, dullness, and fine lines.
XinAi Bottle | Intimate Care
Product Advantages:By strengthening the structure and supportive function of the basement membrane, it promotes the regeneration and firmness of skin tissue, helping to restore and maintain the skin’s firmness and comfort.
XinYang Bottle | Hair Follicle Care & Anti-Hair Loss
Product Advantages:Enhances the structural integrity of hair follicles, improves the follicular microenvironment, and reduces follicle miniaturization, supporting effective anti-hair loss and hair-strengthening.
As consumer demand for aesthetic medicine products continues to grow, VEMINSYN has seized this market opportunity and committed itself to continuous R&D and innovation.Our successful participation in the conference marks an important milestone for VEMINSYN and Suzhou Shiguang Pharmaceutical in the aesthetic medicine field.Through the AMWC China platform, the company aims to further elevate its brand influence, build close partnerships with more industry players, jointly drive the development of the aesthetic medicine industry, and help more people achieve their goals of health and beauty.
About Suzhou Shiguang Pharmaceutical
Suzhou Shiguang Pharmaceutical Biotechnology Co., Ltd., a wholly-owned subsidiary of VEMINSYN, was founded in March 2022, integrating R&D, manufacturing and quality control.
The company has established a full-platform synthesis system covering multiple species including animals, plants, microorganisms and cell-free systems, as well as a full industry chain system for bioactive materials – ranging from raw materials to functional skincare products and end-use medical products. It serves global manufacturers, medical institutions and end-users in pharmaceuticals, cosmetics and other sectors.
It is equipped with Class 100,000 GMP ultra-clean workshops and holds CNAS certification for its scientific quality standards.The company owns a number of utility patents, with a strong focus on product R&D and production.Its products cover medical devices and cosmetics, providing customers with comprehensive OEM/ODM services.
